Verseon’s paper, “VerseAge: A Phenotypic Age Predictor Based on a Shallow Random Network Architecture,” has just been published on IEEE Xplore. This publication follows one of Verseon’s earlier presentations at IEEE FMLDS.
The paper introduces VersAge, Verseon’s method for estimating a person’s biological, rather than chronological, age using routinely collected blood and urine biomarkers along with other physiological measurements. In testing, VersAge achieved a 27% lower error rate than the nearest comparable biological aging clock.
Reliable biological age estimates are increasingly viewed as a foundational tool for aging research, giving scientists a quantitative way to track the effects of interventions aimed at slowing or reversing age-related decline.
Where to Access the Papers:
To view the paper, go to https://doi.org/10.1109/FMLDS67896.2025.00097.
About Verseon
Verseon International Corporation (www.verseon.com) is a clinical-stage, technology-driven pharmaceutical company transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. None of these candidates can be found by other current methods. Verseon's fast-growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancers. The company's supporters and advisors include multiple Nobel laureates, former heads of R&D of major pharmaceutical companies, and various key opinion leaders in medicine.